Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care.
Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care. J Manag Care Pharm. 2013 Jan-Feb; 19(1 Suppl A):S1-53.